Novo Nordisk company profile
Company profile
Novo Nordisk has 68,794 employees and is headquartered in Bagsvaerd, Denmark.
Employing 68,794 people, Novo Nordisk develops, manufactures and sells medicines, with diabetes care, weight management and rare diseases at the core of its portfolio. Products include insulin pens, some with digital dose-guidance features, growth hormone pens, injection needles and the Wegovy pill, an oral treatment for weight management. Customers are reached in Europe, North America, Japan, Korea, Oceania, Southeast Asia, China, Hong Kong, Taiwan, Latin America, the Middle East and Africa. The company has partnerships with Anthropic on medicine development and AI-driven software, and with Orbis Medicines on oral therapies for cardiometabolic diseases.
In the fiscal year ended December 2025, revenue reached 309.1 billion DKK, up 6.4% from the previous year, and net profit amounted to 102.4 billion DKK. The group is headquartered in Bagsvaerd, Denmark, and was founded in 1923 under the name Novo Industri A/S; it changed its name to Novo Nordisk A/S in April 1989. Its shares are also traded on the New York Stock Exchange.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- Denmark
- Headquarters
- Novo Alle 1, 2880, Bagsvaerd
- Employees
- 68,794
- Chief executive
- Maziar Doustdar
- Founded
- 1923
- Fiscal year
- January - December
- Listing
- NOVO.B · Nasdaq Copenhagen
- Currency
- DKK
- ISIN
- DK0062498333
- Website
- novonordisk.com
Novo Nordisk and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Novo NordiskNOVO.B | Denmark | $184.87B | 68,794 | 50.8% | 11.2 |
| AstraZenecaAZN | United Kingdom | $287.12B | 96,100 | 25.8% | 26.6 |
| SanofiSAN | France | $116.52B | 74,846 | 22.3% | 25.5 |
| NovartisNOVN | Switzerland | $305.16B | 75,267 | 34.0% | 32.6 |
| GSKGSK | United Kingdom | $102.04B | 66,841 | 30.5% | 18.0 |
| Roche HoldingROP | Switzerland | $387.48B | 103,249 | 33.1% | 26.7 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
